Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Best of IMIG 2023. Part 2: Peritoneal Mesothelioma
https://doi.org/10.33667/2078-5631-2025-11-33-39
Abstract
The rarity of occurrence, difficulties in diagnosing and staging peritoneal mesothelioma have a significant impact on the formation of a consensus in the treatment of this disease. Pemetrexed remains the drug of choice for both systemic and intraperitoneal chemotherapy for peritoneal mesothelimoma. This article briefly presents the most interesting information on the treatment of peritoneal mesothelioma, presented at the IMIG2023 conference in France.
Keywords
peritoneal mesothelioma,
mesothelioma staging,
peritoneal cancer index,
hyperthermic intraperitoneal chemotherapy (HIPEC)
Supporting agencies: The study had no sponsorship
About the Authors
T. D. Barbolina
N.N. Blokhin National Medical Investigation Centre of Oncology; Scientific and Educational Institute of Continuing Professional Education named after. N.D. Yushchuk, Russian University of Medicine
Russian Federation
Russian Federation
Barbolina Tatyana D. - PhD Med, oncologist, researcher at Oncology Dept of Medicinal Methods of Treatment (Chemotherapeutic) No. 3 N. N. Blokhin National Medical Investigation Centre of Oncology, assistant at Dept of Oncology Scientific and Educational Institute of Continuing Professional Education named after. N. D. Yushchuk, RUM, associate professor at Dept of Postgraduate Education of Physicians (training program “Oncology”) of Dept of Professional Education.
Moscow
S. G. Bagrova
N.N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Bagrova Svetlana G. - PhD Med, oncologist, researcher at Oncology Dept of Medicinal Methods of Treatment (Chemotherapeutic) No. 1.
Moscow
References
1. Leblay N., Leprêtre F., Le Stang N., Gautier-Stein A., Villeneuve L., Isaac S., Maillet D., Galateau-Sallé F., Villenet C., Sebda S. et al. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70 % of Malignant Peritoneal Mesotheliomas. J. Thorac. Oncol. 2017; 12: 724–733.
2. Testa J. R., Cheung M., Pei J., Below J. E., Tan Y., Sementino E., Cox N. J., Dogan A. U., Pass H. I., Trusa S. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 2012; 43: 1022–1025. DOI: 10.1038/ng.912
3. Valenzuela CD, Solsky IB, Erali RA. et al. Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center. Ann Surg Oncol. 2023; 30: 2666–2675.
4. Beal EW, Srinivas S, Shen C. et al. Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the US HIPEC Collaborative. Ann Surg Oncol. 2023; 30: 1840–1849.
5. Ettinger DS, Wood DE, Stevenson J. et al. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal. Version 1.2023. Accessed May 1, 2023. To view the most recent version, visit https://www.nccn.org
6. Kusamura S, Kepenekian V, Villeneuve L. et al. Peritoneal mesothelioma: PSOGI/ EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J. Surg. Oncol. 2021; 47: 36–59.
7. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston, MA: Springer, 1996. Pp. 359–374.
8. Yan TD. et al. A novel tumor-node metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011; 117: 1855–63 and Journal of Thoracic Oncology, 2016.
9. Mackenzie C. Morris et al. The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. Journal of Gastrointestinal Surgery. 2021; 25: 303–318.
10. Sugarbaker PH, Chang D, Jelinek JS. In 100 patients with malignant peritoneal mesothelioma, concerning CT features predicted outcome of treatment. Eur. J. Surg. Oncol. 2021; 47 (9): 2212–2219.
11. Kepenekian V, Elias D, Passot G. et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through RENAPE Database Multi-Institutional Retrospective Study. Eur. J. Cancer. 2016; 65: 69–79.
12. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur. J. Surg. Oncol. 2017; 43: 1228–35.
13. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur. J. Surg. Oncol. 2017; 43: 1228–35.
Review
For citations:
Barbolina T.D., Bagrova S.G. Best of IMIG 2023. Part 2: Peritoneal Mesothelioma. Medical alphabet. 2025;(11):33-39. (In Russ.) https://doi.org/10.33667/2078-5631-2025-11-33-39
Views:
10
Email this article 